RVMD Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of 14.91%. Revolution Medicines, Inc.'s return on equity of -51.27% beat Boston Scientific Corp.'s return on equity of 12.46%.

Revolution Medicines, Inc. has a consensus price target of $108.58, signalling upside risk potential of 11.04%. On the other hand Boston Scientific Corp. has an analysts' consensus of $124.41 which suggests that it could grow by 32.98%. Given that Boston Scientific Corp. has higher upside potential than Revolution Medicines, Inc., analysts believe Boston Scientific Corp. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 0.990, which suggesting that the stock is 1.046% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 50.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 7.22x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of 31.72%. Revolution Medicines, Inc.'s return on equity of -51.27% beat Eli Lilly & Co.'s return on equity of 106.26%.

Revolution Medicines, Inc. has a consensus price target of $108.58, signalling upside risk potential of 11.04%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,112.68 which suggests that it could grow by 4.7%. Given that Revolution Medicines, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Revolution Medicines, Inc. is more attractive than Eli Lilly & Co..

Revolution Medicines, Inc. has a beta of 0.990, which suggesting that the stock is 1.046% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.57% to investors and pays a quarterly dividend of $1.50 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 52.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 16.31x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of 33.68%. Revolution Medicines, Inc.'s return on equity of -51.27% beat Merck & Co., Inc.'s return on equity of 39.63%.

Revolution Medicines, Inc. has a consensus price target of $108.58, signalling upside risk potential of 11.04%. On the other hand Merck & Co., Inc. has an analysts' consensus of $116.07 which suggests that it could grow by 8.08%. Given that Revolution Medicines, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Revolution Medicines, Inc. is more attractive than Merck & Co., Inc..

Revolution Medicines, Inc. has a beta of 0.990, which suggesting that the stock is 1.046% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.05% to investors and pays a quarterly dividend of $0.85 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 4.24x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Solid Biosciences, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of --. Revolution Medicines, Inc.'s return on equity of -51.27% beat Solid Biosciences, Inc.'s return on equity of -77.74%.

Revolution Medicines, Inc. has a consensus price target of $108.58, signalling upside risk potential of 11.04%. On the other hand Solid Biosciences, Inc. has an analysts' consensus of $15.23 which suggests that it could grow by 136.14%. Given that Solid Biosciences, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Solid Biosciences, Inc. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 0.990, which suggesting that the stock is 1.046% less volatile than S&P 500. In comparison Solid Biosciences, Inc. has a beta of 2.688, suggesting its more volatile than the S&P 500 by 168.768%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solid Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Solid Biosciences, Inc. pays out -- of its earnings as a dividend.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Solid Biosciences, Inc. quarterly revenues of --. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Solid Biosciences, Inc.'s net income of -$45.8M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Solid Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 20.36x for Solid Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.